Latest Actinic keratosis Stories
WILMINGTON, Mass., Feb. 26 /PRNewswire/ -- DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) announces that its 2009 corporate highlights and year end financial results press release will be issued on Wednesday, March 3rd at 6:30 a.m. to be followed by a conference call at 8:30 a.m. Wednesday, March 3rd - 8:30 a.m. E.T. If calling from the U.S. or Canada use the following toll-free number: 800-647-4314 Password - DUSA For International callers use 502-498-8422 A replay of the call will be...
WILMINGTON, Mass., Feb. 2 PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (Nasdaq: DUSA), a specialty pharmaceutical company focused primarily on the development and marketing of its Levulan(®) Photodynamic Therapy (PDT) technology platform for the prevention and treatment of dermatological skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the 12th Annual BIO CEO & Investor Conference. The conference is...
BALLERUP, Denmark, Feb. 1 /PRNewswire-USNewswire/ -- LEO Pharma today announced that in a Phase III study, PEP005 (ingenol mebutate) Gel, the company's lead candidate for the topical treatment of actinic (solar) keratosis (AK) or pre-cancerous lesions, met its primary clinical endpoint of complete clearance of AK lesions in non-head locations. Findings from the REGION Ib study in body AK support results from the earlier REGION-I trial, a study evaluating PEP005 for the treatment of AK on...
NEWPORT COAST, Calif., Jan. 11 /PRNewswire-FirstCall/ -- Solta Medical, Inc. (Nasdaq: SLTM) today announced the donation of a Fraxel re:store laser system to the Grossman Burn Foundation, the philanthropic arm of the Grossman Burn Center, a worldwide leader in innovative treatment and care for burn patients and their families. The Fraxel re:store system will be used to reduce the appearance of scarring caused by traumatic thermal damage. "Solta Medical is pleased to donate a Fraxel re:store...
WILMINGTON, Mass., Nov. 10 /PRNewswire/ -- The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan(®) Photodynamic Therapy (PDT) may reduce the rate of recurrence of squamous cell carcinomas (SCCs) in solid organ transplant recipients (SOTRs), a population with a high incidence of nonmelanoma skin cancer. This pilot study, which will also appear in the print version of the December issue of Dermatologic...
WILMINGTON, Mass., Nov. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (Nasdaq GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Merriman Curhan Ford Investor Summit 2009 on Tuesday, November 10, 2009 at 10:00 a.m. ET at the Hotel Sofitel in New York...
WILMINGTON, Mass., Nov. 3 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (Nasdaq: DUSA) announces that its corporate highlights and third quarter financial results press release will be issued on Friday, November 6 at 6:30 a.m. to be followed by a conference call at 8:30 a.m. Friday, November 6 - 8:30 a.m. E.T. If calling from the US or Canada use the following toll-free number: 800.647.4314...
WILMINGTON, Mass., Oct. 28 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that global sales volumes of the Levulan® Kerastick®, an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform, surpassed one million units. "The achievement of this milestone signifies that dermatologists in the U.S. and abroad continue to embrace Levulan PDT for Grade 1 and 2...
BRISTOL, Tenn., Oct. 23 /PRNewswire/ -- Driver Aric Almirola is lending his voice to a national public education program to raise awareness of actinic keratosis (AK) -- a potential early warning sign of skin cancer -- as well as the long-term consequences of sun damage over a lifetime. The national campaign, "Is it AK or OK?" is sponsored by Graceway Pharmaceuticals, LLC, in partnership with The Skin Cancer Foundation. Graceway is the primary sponsor of the No. 15 NASCAR Camping World...
Second Consecutive Year DUSA Has Been Recognized WILMINGTON, Mass., Oct. 21 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(R)( )(Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that it has been named to Deloitte's Technology Fast 500 list. For the second consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications and life sciences companies in North America in terms of percentage...
